Gimat

Vivante Health Announces Study Findings to Support the Clinical Validation of the GIMate

Retrieved on: 
Thursday, September 23, 2021
Clinical trial, PPA, JMIR, Diagnosis, Health, Duke University, FDA, MD, Irritable bowel syndrome, CEO, NPA, Disease, Paradox of tolerance, Lactose intolerance, History, Gimat, Medical device, Dietary supplement, Health insurance

HOUSTON, Sept. 23, 2021 /PRNewswire/ -- Vivante Health , the leading digital solution for digestive health and disease, announced study findings to support the clinical validation of their novel handheld breath testing device, the GIMate.

Key Points: 
  • HOUSTON, Sept. 23, 2021 /PRNewswire/ -- Vivante Health , the leading digital solution for digestive health and disease, announced study findings to support the clinical validation of their novel handheld breath testing device, the GIMate.
  • "These findings support the clinical foundation of the GIMate and will help us launch a broad range of potential novel clinical applications to support our members with their digestive health," Vivante Health's CEO Bill Snyder shared.
  • Vivante Health is planning to apply the findings to help symptomatic individuals without a diagnosis as well as those with common diagnoses such as Irritable Bowel Syndrome.
  • Vivante Health is an innovative digital healthcare company reinventing the way chronic conditions are managed, gut first.